Watts Gwilliam & Co. LLC Purchases 128 Shares of Amgen Inc. (NASDAQ:AMGN)

Watts Gwilliam & Co. LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,651 shares of the medical research company’s stock after purchasing an additional 128 shares during the quarter. Amgen comprises 1.0% of Watts Gwilliam & Co. LLC’s investment portfolio, making the stock its 24th biggest holding. Watts Gwilliam & Co. LLC’s holdings in Amgen were worth $4,626,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Strategic Financial Concepts LLC bought a new position in Amgen during the 2nd quarter valued at approximately $26,000. MGO One Seven LLC increased its holdings in shares of Amgen by 17.5% during the second quarter. MGO One Seven LLC now owns 7,113 shares of the medical research company’s stock valued at $2,223,000 after acquiring an additional 1,061 shares in the last quarter. Angeles Wealth Management LLC raised its position in shares of Amgen by 12.3% in the 2nd quarter. Angeles Wealth Management LLC now owns 828 shares of the medical research company’s stock worth $259,000 after purchasing an additional 91 shares during the last quarter. LPL Financial LLC boosted its stake in Amgen by 9.9% in the 2nd quarter. LPL Financial LLC now owns 746,946 shares of the medical research company’s stock worth $233,383,000 after purchasing an additional 66,983 shares in the last quarter. Finally, Private Wealth Partners LLC grew its position in Amgen by 30.0% during the 2nd quarter. Private Wealth Partners LLC now owns 1,299 shares of the medical research company’s stock valued at $406,000 after purchasing an additional 300 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.8 %

Amgen stock opened at $264.21 on Friday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The firm has a market capitalization of $142.02 billion, a price-to-earnings ratio of 33.83, a P/E/G ratio of 2.91 and a beta of 0.56. The firm has a 50 day moving average of $280.24 and a 200 day moving average of $309.15. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company’s revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the business posted $4.96 earnings per share. As a group, research analysts predict that Amgen Inc. will post 19.53 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.60%. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s payout ratio is presently 121.90%.

Analysts Set New Price Targets

Several brokerages have issued reports on AMGN. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. William Blair restated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Redburn Partners cut their target price on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Piper Sandler reduced their target price on Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a report on Thursday, January 2nd. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $317.30.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.